---
title: "BCYC.US (BCYC.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BCYC.US/news.md"
symbol: "BCYC.US"
name: "BCYC.US"
parent: "https://longbridge.com/en/quote/BCYC.US.md"
datetime: "2026-06-10T11:02:09.523Z"
locales:
  - [en](https://longbridge.com/en/quote/BCYC.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BCYC.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BCYC.US/news.md)
---

# BCYC.US (BCYC.US) — Related News

### [Bicycle Therapeutics presents initial Duravelo-2 data showing comparable ORR and lower toxicity in mUC](https://longbridge.com/en/news/287274269.md)
*2026-05-21T21:13:00.000Z*
> Bicycle Therapeutics reported initial Duravelo-2 data for zelenectide in metastatic urothelial cancer, showing a 65% unc

### [Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | BCYC Stock News](https://longbridge.com/en/news/287272414.md)
*2026-05-21T13:00:28.000Z*
> Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | BCYC Stock News

### [Needham Reaffirms Their Buy Rating on Bicycle Therapeutics (BCYC)](https://longbridge.com/en/news/285373390.md)
*2026-05-06T12:03:23.000Z*
> Needham's Ami Fadia has reaffirmed a Buy rating on Bicycle Therapeutics (BCYC) with a price target of $15.00. Fadia, who

### [Analyst Initiates Buy Rating on Nuzetide Developer, Citing Differentiated Efficacy in Urothelial Cancer and Advancing Pancreatic Cancer Program](https://longbridge.com/en/news/284818639.md)
*2026-04-30T18:15:19.000Z*
> TD Cowen analyst Tara Bancroft has initiated a Buy rating on BCYC stock, citing the promising efficacy of nuzefatide in 

### [Bicycle Therapeutics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 887 K](https://longbridge.com/en/news/284755489.md)
*2026-04-30T11:12:30.000Z*
### [Bicycle Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 887 K](https://longbridge.com/en/news/284754275.md)
*2026-04-30T11:07:25.000Z*
### [Bicycle Therapeutics | 10-K: FY2025 Revenue Beats Estimate at USD 72.59 M](https://longbridge.com/en/news/283977335.md)
*2026-04-24T10:06:12.000Z*
### [Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting | BCYC Stock News](https://longbridge.com/en/news/283520201.md)
*2026-04-21T06:31:00.000Z*
> Bicycle Therapeutics plc (NASDAQ: BCYC) announced its participation in the 2026 ASCO Annual Meeting, featuring an oral p

### [Bicycle Therapeutics: Early EphA2-Targeted Data and Multi-Tumor Expansion Potential Support Buy Rating and Upside to Valuation](https://longbridge.com/en/news/283362749.md)
*2026-04-20T13:15:36.000Z*
> Bicycle Therapeutics received a Buy rating from Needham analyst Ami Fadia, who set a $15.00 price target. The positive o